Biotech has proven to be an excellent sector for investors for an extended period of time and considering the sort of work many companies are doing, it is safe to assume that it is going to continue to throw up excellent opportunities.

There are plenty of companies that present excellent opportunities but at the same time, an investor needs to do his research well in order to identify those. Keeping a close eye on the market is one way of going about it and on that note, here is a look at three biotech stocks to watch.

Sernova (SVA) (SEOVF)

Nearly 100 years after the discovery of insulin, Sernova (TSX:SVA) (OTC:SEOVF) is advancing the treatment for type 1 diabetes. Its implantable Cell Pouch™ technology received FDA clearance and is currently intrials in the US. Sernova’s Cell Pouch™, combined with its immune protection technology, offers therapeutic cells local protection from immune system attack.

Earlier this month the company announced a key breakthrough. Sernova Corp. has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.

Why This Matters

The detection of fasting C-peptide in the bloodstream of its first patient, in addition to Sernova’s recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body’s need for insulin production. This is an important step forward and “evidence of ongoing islet engraftment within the Cell Pouch,” according to the company.

[See How The Sernova Cell Pouch Could Change Drug Delivery Forever]

TrovaGene (TROV)

The first penny stock to consider in this regard is that of TrovaGene Inc (NASDAQ:TROV). On Tuesday, the company provided updates on the clinical trials on its oncology compound Onvansertib. The updates from the Phase 1b and 2 of the clinical trials proved to be highly positive and that had a major effect on the stock price as well.

On Tuesday, the TrovaGene stock price soared by as much as 60% on the back of the positive update. However, it should be noted that a 60% jump on the back of a positive update is probably on the higher side and hence, investors should watch this stock closely at this point.

Aclaris Therapeutics (ACRS)

On the other hand, Aclaris Therapeutics Inc (NASDAQ:ACRS) has managed to be on a roll for much of October. Its stock has gained as much as 50% so far. Aclaris is involved in developing treatments for immuno-inflammatory conditions. This month the company announced a decision to divest from its product RHOFADE cream. The intellectual property for the same has also been passed on to EPI Health, LLC.

While that was one piece of positive news, the other trigger cam on October 8 when it emerged that the company had filed a patent infringement lawsuit against Taro Pharmaceuticals. It is believed that Taro’s product ANDA is a generic version of RHOFADE. Investors should watch this stock keenly over the next weeks and see how it moves.

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.